Evidence map›Paper›PMID 40127100›Full record

ArticleCell reports2025

Ca

Alexander F Jeans, Zahid Padamsey, Helen Collins, William Foster, Sally Allison, Steven Dierksmeier, William L Klein, Arn M J M van den Maagdenberg, Nigel J Emptage

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Alzheimer's Pathology Enhances Excitatory Synaptic Input and Integration in VTA Dopamine Neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexander F JeansDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK. Electronic address: alexander.jeans@pharm.ox.ac.uk.
Zahid PadamseyDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK.
Helen CollinsDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK.
William FosterDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK.
Sally AllisonDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK.
Steven DierksmeierDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK.
William L KleinDepartment of Neurobiology and Physiology, Northwestern University, Evanston, IL 60208, USA.
Arn M J M van den MaagdenbergDepartments of Human Genetics and Neurology, Leiden University Medical Centre, 2300 RC Leiden, the Netherlands.
Nigel J EmptageDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK. Electronic address: nigel.emptage@pharm.ox.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Synaptic dysfunction is an early pathological phenotype of Alzheimer's disease (AD) that is initiated by oligomers of amyloid β peptide (Aβ

Indexed as

Amyloid beta-PeptidesCalcium Channels, N-TypePresynaptic TerminalsAlzheimer DiseaseAnimalsExocytosisGlycogen Synthase Kinase 3 betaHumansMiceMice, TransgenicProtein Kinase CSignal TransductionSynaptic VesiclesAmyloid beta-PeptidesCalcium Channels, N-TypeGlycogen Synthase Kinase 3 betaProtein Kinase CAlzheimer's diseaseAβ oligomerCa2(+) channelCP: Neuroscienceneurodegenerationneurotransmitter releasesynaptic vesicle

Identifiers

PMID40127100
PMCPMC12799594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.